Bihua Chen's Trading History
| BLSMBlossomHill Therapeutics, Inc. | Aug 10, 2026 | Director, Ten Percent Owner | Uninformative Buy | ― | $49.69M | |
| BBOTBridgeBio Oncology Therapeutics | Jul 06, 2026 | Director, Ten Percent Owner | Uninformative Sell | ― | $46.84M | |
| HLXCHelix Acquisition Corp. III Class A | Jan 26, 2026 | Chairperson and CEO, Director, Ten Percent Owner | Uninformative Buy | 4.97M | $5.12M | |
| MLTXMoonLake Immunotherapeutics | Oct 01, 2025 | Former 10% Owner | Informative Sell | 46.87M | $23.49M | |
| BMEABiomea Fusion | Apr 03, 2023 | Former Director | Informative Buy | 12.00M | $2.28M | |
| ERASErasca | Dec 20, 2022 | Director | Informative Buy | 2.00M | $155.17M |
You May Also Like
Bihua Chen insider profile FAQ
What is the percentage of profitable transactions made by Bihua Chen?
The percentage of profitable transactions made by Bihua Chen is 31%.
What is the average return per transaction made by Bihua Chen?
The average return per transaction made by Bihua Chen is -4.00%.
What stocks does Bihua Chen hold?
Bihua Chen holds: BLSM, MLTX, BMEA, ERAS, BBOT, HLXC stocks.
What was Bihua Chen's most profitable transaction?
Bihua Chen’s most profitable transaction was an Informative Buy of MLTX stock on March 22, 2023. The return on the trade was 144.70%.
What is Bihua Chen's role in BlossomHill Therapeutics, Inc.?
Bihua Chen's role in BlossomHill Therapeutics, Inc. is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.